The type of maintenance therapy did not influence the outcome in either high-risk patients or standard-risk patients. Progression-free survival and overall survival in (A-B) high-risk and (C-D) standard-risk cytogenetic abnormalities by maintenance arm. VT indicates bortezomib plus thalidomide; VP, bortezomib plus prednisone; and NR, not reached.